Corporate team advises on the sale of intelligence solutions provider, Deallus

London-based Deallus, a market-leading provider focused on the global life sciences sector, has been bought by data and analytics company GlobalData Plc. Our corporate team advised the majority shareholders of Deallus, including (amongst others) global private equity investor, Archimed.

The transaction is the first acquisition by the group’s GlobalData Healthcare business and kicks off its ambitious merger and acquisition strategy to support its growth trajectory and vision to become the world’s trusted source of strategic intelligence in the healthcare industry.

Over the last two decades, Deallus has built deep sector expertise through supporting clients in key therapy areas, including oncology, neuroscience, vaccines, rare diseases, cell and gene, and immunology. 

The combination of Deallus and GlobalData Healthcare will create the deepest and broadest bench of life sciences data, insights, and expertise in the market, further enhancing value for clients, as well as creating increased opportunities for employees.

Peter Hempshall, CEO of Deallus, said: “We are very excited to join the GlobalData family both for our teams and our clients. Joining GlobalData Healthcare will enhance the offerings and solutions we can provide in the future as we leverage GlobalData’s extensive research and analytics capability, data and tools and significant investment in AI. Our immediate priority is to ensure we capture the benefits of our combined strength to deepen our insights and better support our clients as they navigate an increasingly complex competitive landscape.”

Corporate partner Natalie Wade, who led the advisory team, said: “Under the leadership of Peter and his team and, with the support of Archimed, Deallus is now a world leading provider of competitive intelligence solutions in the life sciences sector. The companies have excellent synergies and joining GlobalData Healthcare will allow Deallus to continue to flourish.”

The deal team included principal associate Christina O’Brien, who played a key role in delivering the transaction.

Archimed is a long-standing client of ours. Last year we advised Archimed on the sale of Vita Health Group to Spire Healthcare group.

Our content explained